DK1558219T3 - Farmaceutisk formulering af olanzapin - Google Patents

Farmaceutisk formulering af olanzapin

Info

Publication number
DK1558219T3
DK1558219T3 DK03751723T DK03751723T DK1558219T3 DK 1558219 T3 DK1558219 T3 DK 1558219T3 DK 03751723 T DK03751723 T DK 03751723T DK 03751723 T DK03751723 T DK 03751723T DK 1558219 T3 DK1558219 T3 DK 1558219T3
Authority
DK
Denmark
Prior art keywords
olanzapine
pharmaceutical formulation
monosaccharide
oligosaccharide
polysaccharide
Prior art date
Application number
DK03751723T
Other languages
English (en)
Inventor
Stanka Perc
Ivanka Banko
Ivanka Kolenc
Original Assignee
Krka Tovarna Zdravil D D Novo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32173824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1558219(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Tovarna Zdravil D D Novo filed Critical Krka Tovarna Zdravil D D Novo
Application granted granted Critical
Publication of DK1558219T3 publication Critical patent/DK1558219T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
DK03751723T 2002-10-18 2003-10-16 Farmaceutisk formulering af olanzapin DK1558219T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200255A SI21303A (sl) 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina
PCT/SI2003/000036 WO2004035027A1 (en) 2002-10-18 2003-10-16 Pharmaceutical formulation of olanzapine

Publications (1)

Publication Number Publication Date
DK1558219T3 true DK1558219T3 (da) 2007-10-29

Family

ID=32173824

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03751723T DK1558219T3 (da) 2002-10-18 2003-10-16 Farmaceutisk formulering af olanzapin

Country Status (18)

Country Link
US (2) US20050288276A1 (da)
EP (1) EP1558219B1 (da)
AT (1) ATE374600T1 (da)
AU (1) AU2003269792A1 (da)
CA (1) CA2502582C (da)
CY (1) CY1107819T1 (da)
DE (1) DE60316714T2 (da)
DK (1) DK1558219T3 (da)
EA (1) EA008516B1 (da)
ES (1) ES2295626T3 (da)
HR (1) HRP20050342B1 (da)
NO (1) NO20052408L (da)
PL (1) PL206217B1 (da)
PT (1) PT1558219E (da)
RS (1) RS51488B (da)
SI (2) SI21303A (da)
UA (1) UA89349C2 (da)
WO (1) WO2004035027A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2083622B1 (da) * 1970-03-27 1975-08-22 Sankyo Co
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
CA2471341C (en) * 2001-12-24 2012-01-24 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions

Also Published As

Publication number Publication date
EA200500671A1 (ru) 2005-10-27
AU2003269792A1 (en) 2004-05-04
CA2502582C (en) 2010-08-03
HRP20050342A2 (hr) 2006-04-30
EP1558219A1 (en) 2005-08-03
RS20050292A (en) 2007-08-03
EP1558219B1 (en) 2007-10-03
PT1558219E (pt) 2008-01-04
PL206217B1 (pl) 2010-07-30
WO2004035027A1 (en) 2004-04-29
DE60316714D1 (de) 2007-11-15
RS51488B (en) 2011-04-30
NO20052408L (no) 2005-07-04
ATE374600T1 (de) 2007-10-15
UA89349C2 (uk) 2010-01-25
NO20052408D0 (no) 2005-05-13
CY1107819T1 (el) 2013-06-19
HRP20050342B1 (hr) 2013-11-08
SI21303A (sl) 2004-04-30
DE60316714T2 (de) 2008-07-17
PL376413A1 (en) 2005-12-27
ES2295626T3 (es) 2008-04-16
CA2502582A1 (en) 2004-04-29
EA008516B1 (ru) 2007-06-29
US20050288276A1 (en) 2005-12-29
SI1558219T1 (sl) 2008-02-29
US20110319395A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DK0991407T3 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
RS50360B (sr) Farmaceutske formulacije derivata platine
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DE60019334D1 (de) Antivirale arznei
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2005065639A3 (en) Novel pharmaceutical compositions
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
NO20051261L (no) Morfin-6-glukuronidsalt
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
HRP20050466A2 (en) Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
NO20065853L (no) Hydrogelinterferonformuleringer